Drug Combination Details
| General Information of the Combination (ID: C42706) | |||||
|---|---|---|---|---|---|
| Name | Methylglyoxal NP Info | + | 5-fluorouracil Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CDK4 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CDK6 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| In-vivo Model | BALB/c mice model inoculated with 4T1. 1 * 106 4T1 cells were subcutaneously injected into the mammary fat pad region of BALB/c mice to develop solid tumors. | |||||
| Experimental
Result(s) |
MG could be a potential candidate for combination therapy to reduce the toxicity burden of 5-FU without any toxic impact on host cells. | |||||
